Skip to content

Comparing the effects of stem cells, and rehabilitation therapy for the treatment of knee osteoarthritis

Comparing the effects of human adipose-derived mesenchymal stem cells, and rehabilitation therapy for the treatment of knee osteoarthritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047124
Enrollment
Unknown
Registered
2021-06-08
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

1 group:Single intra-articular injection of HADMSCs
2 group:Rehabilitation therapy daily, five days a week, for up to 8 weeks

Sponsors

Damascus University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Males and females aged 18 to 70 years; 2.Radiological diagnosis of osteoarthritis using the American College of Rheumatology criteria; 3.Radiological grading of Grade II–III osteoarthritis (OA) of the knee as determined by a qualified radiologist using the Kellgren and Lawrence system; 4.Medial or lateral compartment OA; 5.Less than 5 degrees varus or valgus knee deformity as measured by the long mechanical axis of the knee on X-ray; 6.A minimum pain score of equal or greater than 4/10 on a visual analogue scale (VAS).

Exclusion criteria

Exclusion criteria: 1.Previous meniscectomy/significant partial meniscectomy or other knee-related surgery within the last 12 months; 2.Previous intra-articular injectable therapies within the last 6 months; 3.The patients who have meniscus injury of knee joint need surgical repair; 4.The patients who have severe coagulation disorders or cardiopulmonary conditions; 5.The women who are pregnant or nursing; 6.There are electronic implants such as pacemakers in the body; 7.The patients who are infected the HIV, the virus of hepatitis or syphilis or Bleeding disorders; 8.The patients with severe cognitive impairment who cannot follow instructions to complete the treatment; 9.History of cancer; 10.Immunodeficiency patients; 11.History of systemic illness or significant organ impairment/failure (i.e., renal failure); 12.The patients who have congenital or acquired knee malformation.

Design outcomes

Primary

MeasureTime frame
International Knee Function Score;

Secondary

MeasureTime frame
Visual Analogue Scale (VAS);

Countries

Syria

Contacts

Public ContactCheng Hong

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

1518975384@qq.com+86 15500023752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026